The cell therapy market encompasses the biotechnology and healthcare sector focused on the development and administration of live cells to treat, prevent, or cure diseases. It involves utilizing autologous or allogeneic cells that are often modified in a laboratory to regenerate damaged tissue, restore cellular function, or targetedly destroy diseased cells.
The global preimplantation genetic testing market was valued at USD 636.4 million in 2024 and USD 690.2 million in 2025, and it is projected to reach USD 1,135.0 million by 2030, growing at a compound annual growth rate (CAGR) of 10.5%.
Download PDF Brochure:https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=605
The cell therapy market is primarily driven by the expanding pipeline and clinical success of approved advanced therapies, particularly autologous CAR-T treatments, alongside an increasing global disease burden in oncology, rising research funding, and a shift toward personalized medicine. However, market expansion is heavily restrained by high manufacturing costs and complex processing workflows, combined with underdeveloped or uncertain reimbursement frameworks that limit widespread clinical adoption. Lucrative opportunities exist in the development of platformized, modular manufacturing solutions, investment in allogeneic (off-the-shelf) cell therapy segments, and the expansion into new cell types and advanced gene-editing tools like CRISPR-Cas9. Despite these prospects, the industry faces key challenges, including acute shortages of a skilled workforce capable of handling multi-step automation, legacy manufacturing bottlenecks that inflate production expenses, stringent and evolving regulatory approvals, and the logistical complexities of maintaining strict cold-chain infrastructure and end-to-end traceability.
The target customers for the cell therapy market are primarily institutional healthcare providers, including public and private hospitals, specialized cancer care centers, clinical research institutions, and regenerative medicine hubs, serving diverse clinical populations such as oncology, rare genetic disease, and autoimmune patients. These customers require highly sophisticated medical infrastructure, advanced clinical expertise, and specialized laboratory setups to effectively manage complex administrations and mitigate severe adverse risks. They strongly prefer personalized and targeted treatment options, such as autologous and CAR-T cell therapies, that yield favorable safety profiles, high clinical efficacy, and long-lasting remissions compared to traditional options. Their purchasing behavior is heavily institutionalized, driven by rigorous clinical trial outcomes, regulatory approvals, strong alignment with robust healthcare reimbursement or insurance frameworks, and collaborative procurement agreements with biotechnology firms and contract development and manufacturing organizations (CDMOs).
Market entry, expansion, and profitability in the cell therapy market are heavily shaped by stringent regulatory pathways, accelerating technological innovations, and substantial economic barriers. Regulators enforce rigorous compliance frameworks, process validation, and strict quality control standards to ensure the safety and potency of living cell products, which can delay commercialization despite supportive expedited approval pathways. Technologically, the industry is transitioning toward fully automated, closed, and modular manufacturing systems alongside advanced gene-editing tools like CRISPR to improve efficiency, scalability, and safety. However, economic factors present significant hurdles, as the high cost of specialized manufacturing facilities, complex supply chains for raw materials and viral vectors, and high single-infusion treatment prices create significant cost pressures that limit scalability and patient access, especially given the currently underdeveloped and uncertain insurance reimbursement frameworks.
The cell therapy market is experiencing a significant shift toward allogeneic and off-the-shelf therapies, which aim to overcome the scalability, high costs, and logistical constraints associated with traditional personalized autologous treatments. Emerging trends are heavily focused on gene editing innovations to create universal donor cells and hypoimmunogenic cell lines that minimize immune rejection, alongside advancements designed to improve solid tumor infiltration and prevent antigen escape. These trends are evolving rapidly, as evidenced by a projected double-digit compound annual growth rate (CAGR) for the overall market ranging from 20.47% to over 33% through the next decade, propelled by expanding clinical pipelines, rising research investments, and accelerating regulatory approvals for advanced therapies.
Download PDF Brochure:https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=605
Technological innovations disrupting the cell therapy market are centered on automation, precision gene editing, and digital transformation to enhance scalability and safety. The widespread adoption of CRISPR-Cas9 genome editing is driving a major shift from autologous to allogeneic off-the-shelf CAR-T therapies, simplifying cell engineering and expanding treatment applicability. Furthermore, the integration of fully closed, automated, and platformized modular bioreactors and manufacturing systems reduces manual process variability, while the incorporation of artificial intelligence and machine learning is increasingly leveraged to optimize critical manufacturing parameters, drug discovery, and cell selection.
In the cell therapy market, short-term hype is primarily visible around early-stage, completely non-invasive optical tracking concepts and intensive social media promotions for consumer wellness or generic fitness tracking, which often outpace current clinical reliability and regulatory approvals. Conversely, long-term structural shifts are firmly anchored in medical-grade infrastructure and precision health management. These permanent changes include the rapid expansion of mobile concierge and home infusion care models driven by tech-enabled smart pumps, a strong consumer pivot toward preventive wellness formalized through subscription-based monthly membership models, and rising institutional integration for aging populations managing long-term health conditions.
Source:https://www.marketsandmarkets.com/Market-Reports/preimplantation-genetic-testing-market-605.html
